After Amgen's recent advance in its patent feud with Regeneron and Sanofi, Bristol Myers Squibb is turning to the Supreme Court—yet again—in a bid to revive a blockbuster verdict. Bristol Myers Squibb ...
A former Bristol-Myers Squibb CFO got good news from an appeals court this week: The U.S. Third Circuit narrowed a securities fraud case against him, saying that prosecutors had misapplied securities ...
After years of courtroom drama and amid a market clash, Bristol Myers Squibb has failed to open a new legal front in its cell therapy war with Gilead Sciences. Monday, the U.S. Supreme Court declined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results